Switching Manufacturers: How to Move a Formula Without Losing Quality

Quick answer: A brand can move a formula to a new manufacturer without losing quality, but only if the transfer is treated as a re-development project rather than a purchase order. The formula is only one of five things that determine how a product turns out; the others are raw material specifications, equipment, process parameters and packaging. A realistic transfer of a health or beauty product takes three to nine months and requires the brand to hold its own master documentation before it starts. The practical first step is to assemble a complete technical file and confirm, in writing, what the outgoing manufacturer is contractually obliged to release.

Key takeaways

• An identical ingredient list does not produce an identical product. Equipment, mixing sequence, temperature and shear rate change the outcome.
• The brand owner — not the factory — should hold the master specification, the approved retention sample and the packaging artwork files.
• Stability testing generally restarts at the new site, which is usually the single longest item on the transfer timeline.
• Regulatory notifications and product registrations are tied to a named manufacturer and must be updated before the new stock is sold.
• Running both factories in parallel for one production cycle costs more per unit but removes the risk of a stock-out during changeover.
• Switching is often the wrong answer to a problem that is really about specification clarity or forecasting.

Who this article is for

This article is written for brand owners, founders and product managers in the health, beauty, supplement and consumer product categories who are considering moving an existing product from one OEM (Original Equipment Manufacturer) or ODM (Original Design Manufacturer) to another. It is also relevant to brands that are adding a second manufacturer for capacity or geographic reasons rather than replacing the first. It assumes the product is already in the market and has an established specification.

Why do brands change manufacturers in the first place?

Most manufacturing changes are triggered by one of six causes: cost, capacity, quality, service, capability or risk. Understanding which one applies matters, because each points to a different solution and only some of them are actually solved by changing supplier.

Cost-driven moves are the most common and the most frequently regretted. A quoted unit price is only comparable if the two quotations describe the same specification, the same batch size, the same packaging and the same testing scope. Capacity-driven moves happen when a brand outgrows a partner that served it well at launch volumes. Quality-driven moves follow a pattern of batch variation or complaints. Capability-driven moves occur when a brand wants a format the current factory cannot produce, such as moving from a capsule to a gummy or from a cream to a serum. Risk-driven moves are strategic: a single-source supply chain is a concentration risk, and adding a second qualified site is a legitimate form of insurance.

Analysis: in Creaton Poh's assessment, the distinction that matters most is whether the problem sits in the factory or in the brief. A brand that has never issued a written specification, and has been approving product by eye, will usually reproduce the same inconsistency at the next factory. That situation is better addressed by writing a proper product development brief than by changing address.

What exactly transfers when a formula moves?

A formula transfer moves a package of information, not a single document. The table below sets out what needs to move, who typically holds it, and what a brand owner should secure before giving notice to the outgoing manufacturer.

Element	Who usually holds it	What the brand should secure
Quantitative formula	Manufacturer, unless assigned by contract	Written confirmation of ownership or a licence to use it elsewhere
Raw material specifications and grades	Manufacturer	Supplier names, grades, trade names and technical data sheets
Manufacturing process parameters	Manufacturer	Mixing order, temperatures, timings, speeds and cooling profile
Finished product specification	Shared	Test parameters with numeric limits, not descriptive words
Stability and challenge test data	Manufacturer or testing laboratory	Full reports, and confirmation of what must be repeated
Packaging artwork and dielines	Brand or design agency	Editable source files and printer specifications
Packaging tooling and moulds	Whoever paid for them	Written confirmation of ownership and physical location
Regulatory notification or registration	Whoever is named as holder	Holder status in the brand's own name where the framework allows
Approved retention samples	Manufacturer	A sealed, dated benchmark sample retained by the brand

Ownership is the point at which most transfers stall. Whether a brand can take a formula elsewhere is determined by the contract signed at the beginning, not by who paid the development fee. This is covered in more detail in the discussion of formula ownership and intellectual property and in the review of contract manufacturing agreement terms.

Documentation, not the physical sample, is what actually transfers between manufacturers.

Which parts of a transfer carry the most risk?

The highest-risk elements are those that are invisible in the ingredient list: raw material grade, equipment geometry and process parameters. Each can change the finished product while the formula on paper stays identical.

Raw material grade and origin

Two materials with the same INCI name or chemical name can behave differently. Particle size, viscosity grade, degree of neutralisation, botanical extraction solvent and country of origin all affect performance. A new factory buying the same nominal ingredient from a different supplier can produce a product with a different texture, colour or scent. The practical control is to specify grade and trade name in the transfer file, not just the ingredient name. This is the same discipline described in the guidance on raw material sourcing and documentation.

Equipment and scale

Mixing vessels differ in shape, blade design, heating method and shear capability. A formula developed on a homogeniser at one site may not emulsify the same way on a different machine, and a batch size that changes from 200 kg to 1,000 kg changes heating and cooling times. These effects are the same ones that cause laboratory formulas to behave differently in production, discussed in the article on scale-up failures.

Packaging compatibility

If the packaging supplier changes at the same time as the manufacturer, two variables move at once. Where possible, transfers should hold packaging constant for the first production run so that any difference can be attributed to a single cause.

Regulatory continuity

Product notifications and registrations identify the manufacturing site. In Malaysia, cosmetic notifications and health product registrations are administered by the National Pharmaceutical Regulatory Agency (NPRA), and a change of manufacturer is a change that must be reflected in the record before the new stock is placed on the market. Export markets have their own equivalents. Fact: the timing of this administrative step, not the technical work, is what most often delays a transfer's first commercial batch.

How long does a manufacturing transfer take?

A realistic transfer of an existing health or beauty product takes three to nine months from signed agreement to first commercial batch, with stability testing usually the longest single item. The table below shows an indicative sequence. Actual durations vary by category, complexity and regulatory framework.

Stage	Indicative duration	Main output
Assemble technical file and confirm ownership	2–6 weeks	Complete transfer dossier
Shortlist and audit candidate factories	3–8 weeks	Audit reports and quotations
Laboratory reproduction and benchmarking	3–6 weeks	Bench sample matched to retention sample
Pilot or trial batch	2–6 weeks	Scale-confirmed process parameters
Stability and microbiological testing	4 weeks accelerated to 12 months real-time	Shelf-life justification
Regulatory record update	2–12 weeks	Updated notification or registration
First commercial batch and release	3–6 weeks	Released stock with certificate of analysis

Accelerated stability testing, conducted at elevated temperature and humidity, is commonly used to support an interim shelf life while real-time testing continues. The internationally recognised reference framework for stability study design is published by the International Council for Harmonisation, and while its guidelines are written for pharmaceuticals, the study design principles are widely adapted in cosmetics and supplements.

What documentation should a brand assemble before approaching a new manufacturer?

The transfer file should be complete enough that a competent new factory could quote and plan without further questions. At minimum it contains the finished product specification with numeric limits, the quantitative formula, raw material specifications with grades and trade names, the process description, the packaging specification with artwork files, the current stability and safety data, the applicable regulatory records, and a sealed retention sample.

A specification written as "smooth, pleasant texture, light fragrance" is not transferable. A specification written as pH 5.2–5.8, viscosity 18,000–24,000 cP at 25°C by a named spindle and speed, total plate count below a stated limit, and a named fragrance at a stated dosage is transferable. The difference between the two determines whether a dispute about the first batch can be settled by measurement or only by argument. The role of batch documentation in that judgement is set out in the guide to certificates of analysis.

A sealed benchmark sample gives a transfer an objective reference point.

How should the first batches at the new factory be verified?

The first batches should be verified against the retained benchmark sample and the written specification, not against memory or expectation. A structured approach compares the trial batch on measured parameters, on sensory attributes assessed by more than one person, and on performance in the actual packaging over time.

A practical sequence is: bench sample first, then a pilot batch at a scale that uses the same equipment type as production, then a full commercial batch. Skipping the pilot stage is the most common shortcut and the most common cause of a failed first commercial run. Where the product is sold in multiple markets, the first batch should also be checked against the label and claim requirements of each destination.

Opinion: brands that run the outgoing and incoming factories in parallel for one full cycle are, in Creaton Poh's view, buying cheap insurance. The additional unit cost of a smaller final batch from the outgoing site is usually far less than the cost of an out-of-stock period during a launch window or festive season. Planning that overlap is a forecasting exercise, and is closely related to the reasoning in the article on how much stock a brand should hold.

What are the common mistakes and red flags?

Mistakes brands make

• Giving notice to the outgoing manufacturer before the technical file has been collected.
• Comparing quotations that describe different batch sizes, testing scopes or packaging.
• Changing packaging supplier and manufacturer in the same move, so problems cannot be isolated.
• Treating an accelerated stability result as a completed shelf-life study.
• Assuming a regulatory record transfers automatically with the product.
• Relying on an unsealed, undated sample as the quality benchmark.

Red flags at a candidate factory

• Willingness to reproduce a competitor's formula without asking about ownership.
• Quoting a firm price before seeing the full specification.
• No documented change-control or deviation procedure.
• Reluctance to allow a physical audit, or to show batch records for a comparable product.
• Certification claims that cannot be checked against the issuing body's public register.

Verifying those claims in person is a separate discipline, and the practical method is set out in the factory audit checklist. Certification schemes such as those operated under the Pharmaceutical Inspection Co-operation Scheme maintain public participating-authority information that can be used as a starting point for verification.

When is switching not the right decision?

Switching is usually the wrong decision when the underlying problem is a specification gap, an unrealistic forecast, or a commercial disagreement that has not been raised directly. In each case the same problem tends to reappear at the next factory, with the transfer cost added on top.

It is also questionable when the product is in a growth phase with unstable demand, when a major regulatory submission is pending, or when the brand does not yet hold the documentation required to brief a new partner. A useful test is whether the brand can describe, in numbers, what "correct" looks like. If it cannot, the first project is to write that specification, not to change supplier.

Frequently asked questions

Can a manufacturer refuse to release the formula?

Yes, if the contract does not assign ownership or grant a transfer right. Where the manufacturer developed the formula at its own cost, it commonly retains ownership and is under no obligation to release the quantitative composition. What a brand can usually obtain regardless is the ingredient list already disclosed on the label and the finished product specification it approved. The practical remedy is contractual and needs to be addressed before development starts, not at the point of exit.

Will the new factory be able to match the product exactly?

An exact match is uncommon on the first attempt, and a close match is a realistic target. Differences in raw material lots, equipment and process typically produce small variations in colour, viscosity or scent. The relevant question is whether those variations fall inside the agreed specification limits and whether a consumer would notice them. This is why an agreed numeric specification and a sealed benchmark sample matter more than a verbal description.

Does the shelf life have to be re-established at the new site?

In most cases yes, at least in part. Shelf life is a property of the product as made at a particular site in particular packaging, so a change of site normally requires new stability data to support the claim. Some brands use accelerated data to support an interim shelf life while real-time testing runs in parallel. The requirement varies by product category and market, and should be confirmed with the applicable regulator or a qualified regulatory consultant.

Can two manufacturers make the same product at the same time?

Yes, and dual sourcing is a recognised risk-management approach, but it doubles the quality management workload. Each site needs its own qualification, its own stability data where required, and its own entry in the regulatory record. Batch traceability must make clear which site produced which stock. Dual sourcing is generally more practical once volumes are established than during a launch.

How much does a manufacturing transfer cost?

Costs vary too widely by category and complexity for a single figure to be meaningful, but the recurring items are consistent: bench and pilot batch charges, laboratory testing, stability studies, regulatory filing fees, new packaging tooling if the existing tooling cannot move, and the write-off of remaining raw material or packaging stock at the outgoing site. Brands should also budget the internal time required, which is routinely underestimated.

Should the outgoing manufacturer be told at the start?

That is a commercial judgement, but the sequencing matters more than the timing. Notice given before the technical file, retention samples, tooling confirmation and regulatory position have been secured removes the brand's leverage at the exact moment it needs cooperation. A professional handover, conducted under the notice terms already agreed in the contract, generally produces a better outcome than an abrupt exit.

Is a second-source manufacturer worth it for a small brand?

Often not at low volumes, because qualification cost is largely fixed while the benefit scales with revenue at risk. A more proportionate approach for a small brand is to hold a slightly deeper safety stock, keep the technical file current and audit-ready, and maintain informal contact with one or two qualified alternatives, so that a transfer could be started quickly if it became necessary.

Sources and further reading

• National Pharmaceutical Regulatory Agency (NPRA), Malaysia — product notification and registration frameworks: npra.gov.my
• International Council for Harmonisation — quality guidelines, including stability study design: ich.org
• Pharmaceutical Inspection Co-operation Scheme (PIC/S) — GMP inspection cooperation and participating authorities: picscheme.org
• World Health Organization — norms, standards and guidelines for pharmaceutical production, including technology transfer: who.int

Scope and limitations

This article describes general practice in health, beauty, supplement and consumer product manufacturing, with particular reference to the Malaysian regulatory environment. Timelines and cost items are indicative ranges drawn from common industry practice, not measured data from a specific study, and they vary substantially by product category, batch size and destination market. Regulatory requirements change and differ between jurisdictions. Nothing here is legal, regulatory or contractual advice; specific transfers should be confirmed with the applicable regulator and with qualified legal and technical advisers before action is taken.

---

Disclosure: Creaton Poh is the pen name of Poh Tze Kheng, founder of the ORIZI Group, a Malaysian OEM/ODM manufacturer. This article is educational and independent, and is not promotional.

Written by Creaton Poh
Industry Researcher • Author • Vlogger • Manufacturing Strategist
Turning ideas into products. Turning experience into knowledge.

Connect with Poh Tze Kheng on LinkedIn.